<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased levels of circulating VEGF-A have been demonstrated in patients with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and are associated with progressive disease and poor clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the role of VEGF-A in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> on a molecular level in order to identify the mechanism of VEGF-A-promoted <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> and to identify the potential targets for therapy </plain></SENT>
<SENT sid="2" pm="."><plain>We used a model in which Daudi (human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells were transduced with VEGF-A165 or an empty vector (negative control) and subcutaneously injected in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOD</z:e>/<z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="3" pm="."><plain>The weight of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> overexpressing VEGF-A was increased 4-fold compared to that of control <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (p&lt;0.0001), whereas no in vitro growth advantage was demonstrated upon VEGF-A overexpression </plain></SENT>
<SENT sid="4" pm="."><plain>VEGF-A-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were associated with increased microvessel densities (p=0.004) and increased <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cell proliferation (Ki67; p&lt;0.001) compared to control <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>VEGF-A-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were characterised by upregulation of phosphorylated STAT-4 and STAT-6 and downregulation of phospho-p27(KIP1), a crucial cell cycle inhibitor (p&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>This was accompanied by increased levels of phosphorylated receptor tyrosine kinases, including EGFR (ErbB-2 and ErbB-4, p&lt;0.05), an upstream regulator of STAT proteins </plain></SENT>
<SENT sid="7" pm="."><plain>We demonstrated that various mouse-derived cytokines produced by mouse-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> stromal cells are upregulated in VEGF-A-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> compared to control <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>These results indicate an important role for the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> microenvironment in paracrine promotion of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> in response to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-derived VEGF-A </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-derived VEGF-A promoted <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> in a paracrine loop by activation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> stromal cells </plain></SENT>
<SENT sid="10" pm="."><plain>Our study reveals VEGF-A and STAT proteins as potential additional targets in the treatment of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>